| 000 | 01959cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031510.0 | ||
| 008 | 160517s2015 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.01.M.Sc.2015.Ra.D | ||
| 100 | 0 | _aRamy Fawzy Mahmoud | |
| 245 | 1 | 0 |
_aDexmedetomidine as an Adjuvant to Bupivacaine in ultrasound-guided thoracic paravertebral block for breast cancer surgeries : _bEfficacy of two different doses / _cRamy Fawzy Mahmoud ; Supervised Neamat Ibrahim , SaharAbdelhalim , Abeer Ahmed |
| 246 | 1 | 5 |
_aاستخدام عقار"الديكسميديتوميدين" كعقار مساعد ل"البوبيفاكين" في احصار جنبي الفقار الصدربأستخدام السونار في عمليات سرطان الثدي : _b مقارنة بين جرعتين مختلفتين |
| 260 |
_aCairo : _bRamy Fawzy Mahmoud , _c2015 |
||
| 300 |
_a78 Leaves : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Anaesthesia | ||
| 520 | _aThis study was conducted on 90 patients divided equally into 3 groups receiving either dexmedetomidine 0.5 og/kg (groupBD0.5) or dexmedetomidine 1 og/kg (groupBD1) added to Bupivacaine 0.25% or Bupivacaine 0.25% alone (group B) in TPVB with general anaesthesia in females undergoing MRM. Postoperative pain scores and opioid requirements were significantly lower in the first 24 hours in both groups BD0.5 and group BD1 | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aBreast Cancer | |
| 653 | 4 | _aDexmedetomidine | |
| 653 | 4 | _aETCO | |
| 700 | 0 |
_aAbeer Ahmed , _eSupervisor |
|
| 700 | 0 |
_aNeamat Ibrahim , _eSupervisor |
|
| 700 | 0 |
_aSaharAbdelhalim , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSoheir _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c56518 _d56518 |
||